Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 150
Filtrar
2.
Autoimmun Rev ; 5(3): 180-6, 2006 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-16483917

RESUMEN

The "Euro-Lupus Cohort" is composed by 1000 patients with systemic lupus erythematosus (SLE) that have been followed prospectively since 1991. These patients have been gathered by a European consortium--the "Euro-Lupus Project Group". This consortium was originated as part of the network promoted by the "European Working Party on SLE", a working group created in 1990 in order to promote research in Europe on the different problems related to this disease. The "Euro-Lupus Cohort" provides an updated information on the SLE morbidity and mortality characteristics in the present decade as well as defines several clinical and immunological prognostic factors.


Asunto(s)
Enfermedades Autoinmunes/diagnóstico , Enfermedades Autoinmunes/epidemiología , Lupus Eritematoso Sistémico/diagnóstico , Lupus Eritematoso Sistémico/epidemiología , Edad de Inicio , Anticuerpos Antinucleares/sangre , Enfermedades Autoinmunes/sangre , Enfermedades Autoinmunes/mortalidad , Estudios de Cohortes , Europa (Continente)/epidemiología , Femenino , Estudios de Seguimiento , Humanos , Lupus Eritematoso Sistémico/sangre , Lupus Eritematoso Sistémico/mortalidad , Masculino , Morbilidad , Pronóstico , Estudios Prospectivos , Tasa de Supervivencia
3.
Tissue Antigens ; 64(5): 624-6, 2004 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-15496210

RESUMEN

We report the identification of an HLA-DRB1*01 nucleotide sequence variant in three members of a Caucasian Italian family by using sequence-based typing. The nucleotide sequence of exon 2 observed in the new allele is identical to that of HLA-DRB1*010201 except in position 189 (codon 34) where the adenine of the consensus was replaced by a guanine and it was designated officially as HLA-DRB1*010203* by the WHO Nomenclature Committee.


Asunto(s)
Antígenos HLA-DR/genética , Alelos , Codón , Cartilla de ADN , Cadenas HLA-DRB1 , Humanos , Mutación Puntual , Análisis de Secuencia de ADN
4.
Eur J Immunogenet ; 31(3): 115-9, 2004 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-15182324

RESUMEN

Alport syndrome (AS) is a genetic disease of type IV collagen involving non-homogeneous patterns of inheritance characterized clinically by the presence of progressive haematuric nephritis leading to end-stage renal disease (ESRD), hearing loss and/or ophthalmologic abnormalities. The aim of this study was to investigate, in a cohort of AS patients who had undergone a kidney graft (KG) or who were still on a waiting list for a KG, (a) whether there is a correlation between AS and HLA antigen expression, and (b) long-term graft outcome in transplant patients. The AS cohort was represented by 34 ESRD patients, of whom 25 received a KG and the remaining nine were still on a waiting list. AS transplant patients represented 2.78% of 899 first KGs performed at our centre (Transplantation Department at S. Martino Hospital, Genoa) between 1983 and 2002. Grafts were procured from cadaveric donors in 18 cases and from living, related donors in seven cases. All AS transplant patients had a post-transplant follow-up period of at least 12 months. Results showed that: (i) the frequency of the HLA-DRB1*16 antigen was significantly increased in the whole AS cohort as compared to 128 healthy subjects (HS) (corrected P-value 0.0026; relative risk 7.20) as well as to 232 non-AS ESRD patients on a waiting list for KG (corrected P-values 0.0156; relative risk 4.67); (ii) 5- and 10-year graft survivals in the AS transplant patients were 80 and 73%, respectively, and did not differ from those of a control group represented by 25 non-AS KG recipients matched for sex, age, number of HLA mismatches and immunosuppressive treatment. Increased frequency of HLA-DRB1*16 in AS patients may reflect a linkage disequilibrium with genes coding for collagen synthesis.


Asunto(s)
Antígenos HLA-DR/genética , Trasplante de Riñón , Nefritis Hereditaria/inmunología , Nefritis Hereditaria/cirugía , Adulto , Estudios de Cohortes , Femenino , Expresión Génica , Supervivencia de Injerto , Antígenos HLA-DR/análisis , Cadenas HLA-DRB1 , Humanos , Masculino , Nefritis Hereditaria/genética , Fenotipo
5.
Clin Exp Immunol ; 135(2): 259-66, 2004 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-14738454

RESUMEN

T-cell-mediated immunoregulation is one of the main mechanisms implicated in induction and maintenance of transplantation tolerance. In this regard, deletion or modulation of xeno/alloantigen-specific T cells, as well as blocking of their interactions with other cell populations, are currently being pursued for tolerance induction in humans as well as nonhuman primates. In order to investigate whether cytotoxic T-lymphocyte antigen-4 (CTLA-4) may represent a suitable target for a T cell depletion approach in nonhuman primate models, we analysed CTLA-4 expression in peripheral blood mononuclear cells (PBMCs) from nonhuman primates and the potential role of two anti-CTLA-4 saporin-conjugated immunotoxins. The analysis was performed in PBMCs from 8 cynomolgus monkeys from Philippines and from Mauritius both at protein level by flow cytometry and at transcriptional level by RT-PCR. In addition, the apoptotic role of the immunotoxins was investigated. The results showed that CTLA-4 was expressed at variable levels depending on the origin of the cynomolgus monkeys and the resting or activated cell condition. CTLA-4 was not expressed on resting Mauritius PBMCs and showed a lower up-regulation upon PMA/PHA activation compared to the Philippines PBMCs that expressed CTLA-4 also before activation. Two CTLA-4 RNA transcripts (672 and 550 bp) were detected with levels variations after cell stimulation. Two anti-CTLA-4 immunotoxins induced in vitro apoptosis of activated PBMCs from both sources of cynomolgus monkeys. This is the first report that documents CTLA-4 expression both at protein and transcriptional level by nonhuman primate PBMCs and provides novel perspectives of xeno/allograft rejection immunotherapy based on CTLA-4 targeting.


Asunto(s)
Antígenos de Diferenciación/análisis , Apoptosis/inmunología , Inmunosupresores/análisis , Inmunotoxinas/inmunología , Linfocitos T/inmunología , Animales , Antígenos CD , Antígeno CTLA-4 , Células Cultivadas , Ensayo de Inmunoadsorción Enzimática/métodos , Femenino , Citometría de Flujo/métodos , Técnica del Anticuerpo Fluorescente Directa/métodos , Tolerancia Inmunológica/inmunología , Inmunoglobulina M/inmunología , Leucocitos Mononucleares/inmunología , Macaca fascicularis , Masculino , ARN/análisis , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos , Transcripción Genética , Regulación hacia Arriba/inmunología
6.
Tissue Antigens ; 62(5): 418-25, 2003 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-14617049

RESUMEN

At present, 128 HLA-Cw alleles have been described. Twenty-four of 128 display critical polymorphisms in contributing to allele identification outside exons 2 and 3. As a matter of fact, complete resolution of Cw*030201, Cw*030202, Cw*0409N, Cw*0501, Cw*0503, Cw*070101, Cw*070102, Cw*070401, Cw*0706, Cw*0711, Cw*0718, Cw*120201, Cw*120202, Cw*150501, Cw*150502, Cw*1701, Cw*1702, Cw*1703, Cw*1801 and Cw*1802 alleles requires nucleotide analysis of exons 1, 4, 5, 6 and 7. Moreover, some alleles (Cw*04010101, Cw*04010102, Cw*07020101 and Cw*07020102) showing nucleotide differences outside the coding regions of HLA-C gene (intron 2) have been reported. High resolution sequence based typing (SBT) developed in this study involves two DNA amplifications and 12 direct sequencing reactions and allows the analysis of HLA-C polymorphisms from exon 1 through exon 8, including intron 2. This typing procedure identifies all 128 Cw alleles described so far. Nevertheless, a number of ambiguous heterozygous typing results may be expected, this being the major drawback of SBT methods. A total of 201 samples were HLA-C typed using SBT strategy here described. The sequence of exons 6, 7 and 8 of HLA-Cw*070102 allele was elucidated. A novel HLA-Cw*07 allele, Cw*0718, was identified in two samples. Cw*0718 differs from the Cw*070101 allele by a unique nucleotide position within exon 6, resulting in an amino acid substitution at codon 324 (Ala-->Val) in the cytoplasmic region of the molecule.


Asunto(s)
Antígenos HLA-C/genética , Análisis de Secuencia de ADN , Humanos , Datos de Secuencia Molecular , Reacción en Cadena de la Polimerasa
7.
Lupus ; 12(7): 560-3, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-12892399

RESUMEN

Our objective was to determine the HLA-DPB1 allele associations of anticardiolipin (aCL) and anti-beta2GPI (a(beta)2GPI) antibodies, and of clinical manifestations of the antiphospholipid syndrome (APS), in systemic lupus erythematosus (SLE). We studied 577 European patients with SLE. aCL and a(beta)2GPI antibodies were measured by ELISA. Molecular typing of HLA-DPB1 locus was performed by polymerase chain reaction-sequence specific oligonucleotide probe (PCR-SSOP) method. aCL showed positive association with -DPB1*1501 (P = 0.005, OR = 7.4), and -DPB1*2301 (P = 0.009, OR = 3.3). a(beta)2GPI showed positive association with -DPB1*0301 (P = 0.01, OR = 1.9), and -DPB1*1901 (P = 0.004, OR = 8.1). In addition, livedo reticularis was associated with -DPB1*1401, and Raynaud's phenomenon with -DPB1*2001. In conclusion, HLA-DPB1 locus may contribute to the genetic predisposition to develop antiphospholipid antibodies and clinical manifestations of the APS in patients with SLE.


Asunto(s)
Anticuerpos Anticardiolipina/sangre , Autoanticuerpos/sangre , Glicoproteínas/inmunología , Antígenos HLA-DP/análisis , Lupus Eritematoso Sistémico/inmunología , Adolescente , Adulto , Anciano , Síndrome Antifosfolípido/genética , Síndrome Antifosfolípido/inmunología , Femenino , Predisposición Genética a la Enfermedad , Cadenas beta de HLA-DP , Humanos , Lupus Eritematoso Sistémico/genética , Masculino , Persona de Mediana Edad , beta 2 Glicoproteína I
8.
Eur J Cancer ; 39(9): 1242-50, 2003 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-12763212

RESUMEN

The aim of this study was to investigate the prognostic significance of a panel of biological parameters in patients with radically resected non-small cell lung cancers (NSCLC). 269 cases with pathological stage I-IIIA NSCLC were retrospectively analysed. Immunohistochemistry was performed to detect protein expression of p53, bcl-2, proliferating cell nuclear antigen (PCNA) and CD34. Polymerase chain reaction (PCR)/direct nucleotide sequencing method was used to detect mutations in K-ras (codons 12, 13, 61, exons 1-2). The Kaplan-Meier estimates of survival were calculated for clinical and biological variables using the Cox model for multivariate analysis. Histological subtype and the pathologic tumour extension (pT) were the most powerful clinical-pathological prognostic factors for survival (P=0.030 and P=0.031, respectively), whereas among the biological parameters, p53 overexpression (P=0.032) and K-ras mutation (P=0.078) had a negative prognostic role, as demonstrated by multivariate analysis. Conversely, bcl-2, PCNA and CD34 expression were not correlated with survival. Statistically significant associations between p53 expression and the squamous cell carcinoma (SCC) subtype, bcl-2 expression and SCC subtype, K-ras mutation and p53 negative expression, p53 and bcl-2, bcl-2 and PCNA overexpression were observed. In conclusion, some biological characteristics such as the K-ras and p53 status may provide useful prognostic information in resected NSCLC patients, in addition to the classical clinico-pathological parameters. However, further studies are needed to clarify the value of adopting biological prognostic factor into clinical practice.


Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/química , Neoplasias Pulmonares/química , Proteínas de Neoplasias/análisis , Adulto , Anciano , Anciano de 80 o más Años , Antígenos CD34/análisis , Carcinoma de Pulmón de Células no Pequeñas/cirugía , Carcinoma de Células Escamosas/química , Carcinoma de Células Escamosas/cirugía , Femenino , Genes bcl-2 , Genes p53 , Genes ras , Humanos , Inmunohistoquímica/métodos , Neoplasias Pulmonares/cirugía , Masculino , Persona de Mediana Edad , Técnicas de Amplificación de Ácido Nucleico , Pronóstico , Antígeno Nuclear de Célula en Proliferación/análisis , Modelos de Riesgos Proporcionales , Proteínas Proto-Oncogénicas c-bcl-2/análisis , Estudios Retrospectivos , Análisis de Supervivencia , Proteína p53 Supresora de Tumor/análisis
11.
Ann Med Interne (Paris) ; 153(8): 530-6, 2002 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-12610427

RESUMEN

The "Euro-Lupus Cohort" is composed by 1,000 patients with systemic lupus erythematosus (SLE) that have been followed prospectively since 1991. These patients have been gathered by a European consortium - the "Euro-Lupus Project Group". This consortium was originated as part of the network promoted by the "European Working Party on SLE", a working group created in 1990 in order to promote research in Europe on the different problems related to this disease. The "Euro-Lupus Cohort" provides an updated information on the SLE morbidity and mortality characteristics in the present decade as well as defines several clinical and immunological prognostic factors.


Asunto(s)
Lupus Eritematoso Sistémico/epidemiología , Adolescente , Adulto , Edad de Inicio , Anticuerpos Antinucleares/sangre , Estudios de Cohortes , Europa (Continente)/epidemiología , Femenino , Humanos , Lupus Eritematoso Sistémico/sangre , Lupus Eritematoso Sistémico/mortalidad , Masculino , Persona de Mediana Edad , Pronóstico , Estudios Prospectivos , Tasa de Supervivencia
12.
Blood ; 98(10): 3150-5, 2001 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-11698304

RESUMEN

The hypothesis was tested that amino acid substitutions in specific positions within human leukocyte antigen class I heavy chain would have different impacts on transplant-related mortality (TRM) in patients receiving transplanted bone marrow from unrelated donors. One hundred patients and their unrelated donors were typed by sequence-based typing for the human leukocyte antigen (HLA)-A, -B, and -C loci. All pairs were matched for DRB1, DRB3, DRB4, DRB5, DQA1, and DQB1 loci. Forty pairs were also matched at class I, and 60 pairs had one or more mismatches at class I loci. It was found that substitutions at positions 116 and 114 of class I heavy chain significantly increased the risk for TRM in univariate and bivariate Cox analyses. Conversely, no association between number of multiple mismatches or number of amino acid substitutions and TRM was seen when positions 116 and 114 were adjusted for. Variables predictive of TRM in multivariate Cox analysis were number of cells infused, diagnosis (chronic myeloid leukemia [CML] or non-CML), and amino acid substitution at position 116 or 152. The only variable predictive of severe acute graft-versus-host disease (GVHD) in multivariate Cox analysis was substitution at position 116. Actuarial risk for acute GVHD grade III-IV, TRM, and relapse in pairs with substitutions at position 116 (n = 37) compared to other pairs (n = 63) was, respectively, 36% versus 14% (P =.01), 59% versus 28% (P =.001), and 25% versus 31% (P =.4). In conclusion these data suggest that substitutions at position 116 of class I heavy chain increase the risk for acute GVHD and TRM in patients who receive transplanted bone marrow from unrelated donors.


Asunto(s)
Sustitución de Aminoácidos , Trasplante de Médula Ósea , Codón/genética , Genes MHC Clase I , Histocompatibilidad , Trasplante Homólogo , Adulto , Alelos , Trasplante de Médula Ósea/mortalidad , Supervivencia sin Enfermedad , Exones/genética , Frecuencia de los Genes , Enfermedad Injerto contra Huésped/etiología , Enfermedad Injerto contra Huésped/genética , Enfermedad Injerto contra Huésped/mortalidad , Prueba de Histocompatibilidad , Humanos , Tablas de Vida , Polimorfismo Genético , Modelos de Riesgos Proporcionales , Estudios Retrospectivos , Factores de Riesgo , Análisis de Supervivencia , Donantes de Tejidos , Trasplante Homólogo/mortalidad , Resultado del Tratamiento
13.
J Immunol ; 167(8): 4222-9, 2001 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-11591743

RESUMEN

Immunotoxins containing recombinant human-derived single-chain fragment variable (scFv) reagents (83 and 40) against CTLA-4 (CD152) linked to saporin, a ribosome-inactivating protein, were prepared and tested on CD3/CD28-activated T lymphocytes, MLRs, CTLA-4-positive cell lines, and hemopoietic precursors. Immunotoxins induced apoptosis in activated T lymphocytes and were able to specifically inhibit MLR between T lymphocytes and dendritic cells. The 83-saporin immunotoxin also inhibited the T cell activation in an MLR between T lymphocytes and an EBV-positive lymphoblastoid B cell line. Toxicity tests on hemopoietic precursors showed little or no effects in inhibiting colonies' growth. As the 83 scFv Ab was reactive also with activated mouse T lymphocytes, 83-saporin was tested in a model of tumor rejection consisting of C57BL/6 mice bearing a murine H.end endothelioma cell line, derived from DBA/2 mice. The lymphoid infiltration due to the presence of the tumor was reduced to a high extent, demonstrating that the immunotoxin was actually available and active in vivo. Thus, taking the results altogether, this study might represent a new breakthrough for immunotherapy, showing the possibility of targeting CTLA-4 to kill activated T cells, using conjugates containing scFv Abs and type 1 ribosome-inactivating protein.


Asunto(s)
Antígenos de Diferenciación/inmunología , Rechazo de Injerto/tratamiento farmacológico , Inmunoconjugados , Región Variable de Inmunoglobulina/uso terapéutico , Inmunotoxinas/uso terapéutico , Proteínas de Plantas/uso terapéutico , Abatacept , Animales , Antígenos CD , Antígeno CTLA-4 , Dimerización , Relación Dosis-Respuesta a Droga , Células Madre Hematopoyéticas/efectos de los fármacos , Humanos , Ratones , Ratones Endogámicos DBA , N-Glicosil Hidrolasas/uso terapéutico , Trasplante de Neoplasias/inmunología , Proteínas Inactivadoras de Ribosomas Tipo 1 , Proteínas Inactivadoras de Ribosomas Tipo 2 , Saporinas , Linfocitos T/efectos de los fármacos
14.
Gastrointest Endosc ; 54(5): 595-9, 2001 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-11677475

RESUMEN

BACKGROUND: A preoperative tissue diagnosis of pancreatic cancer is desirable but difficult to obtain. METHODS: Pancreatic brush cytology, salvage cytology, and collection of pancreatic juice were attempted prospectively during ERCP in 34 patients with pancreatic cancer and 11 with chronic pancreatitis. K-ras-2 codon 12 was analyzed for presence and type of point mutations. RESULTS: Brush cytology coupled with salvage cytology had a sensitivity of 74%. The addition of cytologic analysis of pancreatic juice did not substantially improve sensitivity (76%). K-ras-2 was mutated in both cancer (87%) and pancreatitis (40%). The specificity for cytology was 100% and for K-ras-2 mutations 60%. Combining cytology with mutation analysis increased sensitivity to 93% but reduced the positive predictive value. The negative predictive value never exceeded 75%. None of the patients with chronic pancreatitis had cancer develop (median follow-up 60 months). CONCLUSIONS: Pancreatic ductal brushing with salvage cytology is useful in the diagnosis of cancer, whereas cytologic analysis of pancreatic juice can be abandoned. At present, K-ras-2 mutation is not useful for differentiating pancreatic cancer from chronic pancreatitis or the identification of patients with chronic pancreatitis at risk for malignant transformation.


Asunto(s)
Colangiopancreatografia Retrógrada Endoscópica , Genes ras , Neoplasias Pancreáticas/patología , Pancreatitis/genética , Pancreatitis/patología , Adulto , Anciano , Anciano de 80 o más Años , Enfermedad Crónica , Codón , Citodiagnóstico/instrumentación , Citodiagnóstico/métodos , Análisis Mutacional de ADN , Femenino , Humanos , Masculino , Persona de Mediana Edad , Mutación , Conductos Pancreáticos/patología , Jugo Pancreático/citología , Neoplasias Pancreáticas/genética , Neoplasias Pancreáticas/cirugía , Pancreatitis/cirugía , Valor Predictivo de las Pruebas , Estudios Prospectivos , Sensibilidad y Especificidad
15.
Clin Exp Immunol ; 125(3): 391-400, 2001 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-11531946

RESUMEN

The identification of ricin toxin A-chain (RTA) epitopes and the molecular context in which they are recognized will allow strategies to be devised that prevent/suppress an anti-RTA immune response in patients treated with RTA-based immunotoxins. RTA-specific human T-cell lines and T-cell clones were produced by in vitro priming of PBMC. The T-cell clones used a limited set of Vbeta chains (Vbeta1, Vbeta2 and Vbeta8) to recognize RTA epitopes. The use of RTA deletion mutants demonstrated that T-cell lines and T-cell clones from three out of four donors responded to RTA epitopes within the domain D124-Q223, whereas one donor recognized the region I1-D124. The response to RTA peptides of T-cell lines and T-cell clones from two donors allowed the identification of immunogenic segments (D124-G140 and L161-T190) recognized in the context of different HLA-DRB1 alleles (HLA-DRB1*0801, and HLA-DRB1*11011 and B1*03011, respectively). The response to L161-T190 was investigated in greater detail. We found that the HLA-DRB1*03011 allele presents a minimal epitope represented by the sequence I175-Y183 of RTA, whereas the HLA-DRB1*11011 allele presents the minimal epitope M174-I184. RTA peptides and an I175A RTA point mutant allowed us to identify I175 as a crucial residue for the epitope(s) recognized by the two HLA-DRB1 alleles. Failure of T-cell clones to recognize ribosome inactivating proteins (RIPs) showing sequences similar but not identical to RTA further confirmed the role of I175 as a key residue for the epitope recognized in the context of HLA-DRB1*11011/03011 alleles.


Asunto(s)
Antígenos HLA-DR/inmunología , Ricina/inmunología , Linfocitos T/inmunología , Secuencia de Aminoácidos , Células Clonales , Epítopos , Genes Codificadores de la Cadena alfa de los Receptores de Linfocito T , Antígeno HLA-DR3/inmunología , Cadenas HLA-DRB1 , Humanos , Inmunotoxinas , Datos de Secuencia Molecular , Fragmentos de Péptidos/inmunología , Linfocitos T Colaboradores-Inductores , Vacunación
16.
Transfusion ; 41(4): 462-9, 2001 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-11316895

RESUMEN

BACKGROUND: The presence of antibodies to CTLA-4, a negative regulator of T-cell activation, was investigated in multiply transfused patients with malignant and non- malignant hematologic diseases. A previous study showed that, in multiply transfused patients, an immune response against nuclear matrix proteins can be induced by WBCs undergoing apoptosis during RBC unit storage. This study evaluated whether the same phenomenon could be involved in the induction of CTLA-4 antibodies in the patients analyzed. STUDY DESIGN AND METHODS: Patient sera were tested for binding to the recombinant full-length CTLA-4 beta-galactosidase fusion protein by an ELISA. Immuno-fluorescence stainings were performed to analyze the CTLA-4 epitopes recognized by the antibodies and to detect such epitopes in the apoptotic cells present in the RBC units. RESULTS: CTLA-4 antibodies were found in multiply transfused patients with beta-thalassemia (40%) and with other hemolytic diseases (33%) including leukemias (42%). A higher incidence of CTLA-4 antibodies was found in patients receiving non-WBC-reduced blood (88%) than in those receiving WBC-reduced blood (26%). Immunofluorescence staining showed that WBCs undergoing apoptosis in the RBC unit expressed CTLA-4 epitopes. CONCLUSIONS: The apoptotic WBCs present in the RBC units, after cold storage, express CTLA-4 epitopes. These epitopes can be released and induce formation of CTLA-4 antibodies with profound implications in the development of autoimmune disorders and in facilitating tumor dissemination and metastasis.


Asunto(s)
Anticuerpos/inmunología , Antígenos de Diferenciación/inmunología , Transfusión Sanguínea , Enfermedades Hematológicas/inmunología , Enfermedades Hematológicas/terapia , Inmunoconjugados , Abatacept , Adolescente , Adulto , Anciano , Anticuerpos/sangre , Especificidad de Anticuerpos , Antígenos CD , Antígenos de Diferenciación/sangre , Antígeno CTLA-4 , Mapeo Epitopo , Femenino , Enfermedades Hematológicas/sangre , Humanos , Masculino , Persona de Mediana Edad , Proteínas Recombinantes de Fusión/inmunología , Reacción a la Transfusión
19.
Hum Immunol ; 62(2): 133-9, 2001 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-11182222

RESUMEN

Downregulation of HLA class I antigen expression has been reported in a significant proportion of primary breast carcinomas suggesting an escape mechanism from CTL mediated lysis leading to tumor dissemination and metastasis. We have previously reported the biochemical and immunohistochemical analysis of HLA total class I (W6/32 mAb), alpha-chain (Q1/28,TP25.99 mAbs) and beta(2)-microglobulin (Namb-1 mAb) subunits expression in 25 primary breast carcinomas. This study at protein level resulted in the observation of three different HLA class I expression patterns by both techniques: high, low, and absent downregulation patterns. To better characterize the HLA class I antigens downregulation we extended such analysis also at RNA level by RT-PCR using HLA-A, HLA-B, HLA-C, and beta(2)-microglobulin specific primers either in breast cancer or normal tissues derived from the same patient. None (100%) of the alpha-chain genes analyzed in patient tumor tissues showed significant reduction of expression. In 10 patients out of 25 (40%) the beta(2)-microglobulin gene showed complete loss of expression compared with the corresponding normal tissue counterpart, which showed a constitutive expression, whereas in 2 patients (12.5%) its expression was comparable with the normal counterpart. Sequence analysis at genomic level revealed no defects affecting beta(2)-microglobulin gene in those patients showing lack of expression. Also TAP1 and TAP2 genes expression were investigated in order to confirm or exclude involvement of the MHC class I molecules assembling machinery. The RT-PCR approach mainly confirmed our beta(2)-microglobulin biochemical analysis indicating that in breast cancer specimens it is possible to address the HLA class I gene downregulation as a phenomenon occurring at post-transcriptional level mainly affecting the beta(2)-microglobulin gene expression.


Asunto(s)
Neoplasias de la Mama/inmunología , Regulación hacia Abajo/inmunología , Antígenos HLA/biosíntesis , Antígenos de Histocompatibilidad Clase I/biosíntesis , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Transportador de Casetes de Unión a ATP, Subfamilia B, Miembro 2 , Miembro 3 de la Subfamilia B de Transportadores de Casetes de Unión a ATP , Transportadoras de Casetes de Unión a ATP/genética , Transportadoras de Casetes de Unión a ATP/inmunología , Actinas/genética , Anticuerpos Monoclonales/análisis , Western Blotting , Neoplasias de la Mama/química , Regulación hacia Abajo/genética , Femenino , Regulación Neoplásica de la Expresión Génica/inmunología , Antígenos HLA/genética , Antígenos HLA/inmunología , Antígenos de Histocompatibilidad Clase I/genética , Antígenos de Histocompatibilidad Clase I/inmunología , Humanos , Inmunohistoquímica , Células K562 , Microglobulina beta-2/genética , Microglobulina beta-2/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA